Carolien Zeetsen

117 CHAPTER Cognitive i mpairments in patients with GUD predict relapse 6 Table 6.1. Means, standard deviations ( SD ) and proportion correct per domain on the Montreal Cognitive Assessment (MoCA) Domain Scores (MoCA–DS) and Total Score (MoCA–TS), including the number of patients scoring below the cut–off, before (T1) and after (T2) detoxification. MoCA–DS (range) T1 ( n = 39) T2 ( n = 39) Mean ( SD ) % Mean ( SD ) % Executive & visuospatial functions (0–6) 4.36 (1.20) 72.7% 4.74 (1.17) 79.0% Attention (0–6) 5.00 (1.07) 83.3% 5.13 (1.08) 85.5% Language (0–5) 4.40 (1.05) 88.0% 4.66 (0.63) 92.2% Abstract reasoning (0–2) 1.63 (0.62) 81.5% 1.81 (0.44) 90.5% Memory (0–5) 2.94 (1.58) 58.8% 3.52 (1.54) 70.4% Orientation (0–6) 5.84 (0.48) 97.3% 5.79 (0.48) 96.5% MoCA–TS (0–30) 24.16 (3.01) 80.1% 25.65 (2.78) 85.5% n (%) < 25* 56.3% 30.6% Note: % = proportion correct (mean score divided by maximum domain score times 100%); * = significant difference between T1 and T2 p < .005. Table 6.2. Pearson and Spearman correlations between patient characteristics and the Montreal Cognitive Assessment – Total Score (MoCA–TS) both before (T1) and after (T2) detoxification. MoCA–TS T1 T2 Sex –0.196 0.060 Age 0.089 0.101 Number of days used in the past 30 days –0.013 0.003 Daily GHB dose –0.152 0.111 Number of months of daily use –0.180 0.202 Number of months of use in the lifetime –0.143 0.167 GHB exposure score –0.217 0.217 Number of comas experienced 0.978 –0.079